Hammad Ali Fadlalmola
Department of Community Health Nursing, College of Nursing, Taibah University, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia
Khaled Mohammed Al-Sayaghi
Department of Medical Surgical Nursing, College of Nursing, Taibah University, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia; Nursing Division, Faculty of Medicine and Health Sciences, Sana'a University, Sana'a, Yemen
Abdulqader Abdlah Al-Hebshi
Pediatric Hematology Oncology Service, Department of Pediatrics, Prince Mohammed Bin AbdulAziz Hospital, Ministry of National Guard Health Affairs, Medina, Saudi Arabia
Muhanad Alhujaily
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia
Arwa Omar Alyamani
Service of Pediatric Hematology-Oncology, Department of Pediatrics, King Saud Bin Abdul Azizi Collage for Health Science, Riyadh, Saudi Arabia; Princess Noorah Oncology Center, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
Alaa Abdulrhman Alem
Nephrology Service, Department of Medicine, College of Medicine, Taibah University, Medina, Saudi Arabia
Mona Hamza Syrafi
Service of Pediatric Nephrology, Department of Pediatrics, King Salman Bin Abdulaziz Medical City, Medina, Saudi Arabia
Sarah Alem
Nahdi Medical Company, Medina, Saudi Arabia
Afrah Hassan Farhat
Department of Pediatrics, King Khalid University Hospital, Riyadh, Saudi Arabia
Fathi Abdelrazig Mohamed
Department of Pediatrics, Prince Mohammed Bin AbdulAziz Hospital, Ministry of National Guard Health Affairs, Medina, Saudi Arabia
Hager Hassan Abdalrahman
College of Applied Medical Sciences, University of Hafr Albatin, Hafr Albatin, Saudi Arabia
Mohammed Abdelkrim Abdelmalik
Department of Nursing, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia; Faculty of Medicine and Health Sciences, Nursing, University of El Imam El Mahdi Kosti, White Nile, Sudan
Neimat Mahmoud Abdalrhman
Medical Surgical Nursing Department, Al Baha University, Baha, Saudi Arabia
Alamin Mustafa Eltayeb
Al-Neelain University, Faculty of Medicine, Khartoum, Sudan
Abstract
Chronic kidney disease (CKD) is commonly complicated by anemia. Treating dialysis-dependent patients with anemia, including daprodustat and other inhibitors of prolyl hydroxylase of hypoxia-inducible factor, recombinant human erythropoietin (rhEPO), and iron supplements. We conducted this study to test our postulation; daprodustat is superior to rhEPO and other conventional treatments respecting efficacy and safety parameters. We made systematic search through PubMed, Web of Science, Scopus, and Cochrane. Seven unique trials were eventually included for systematic review; six of them with a sample size of 759 patients entered our network meta-analysis (NMA). Daprodustat 25-30 mg was associated with the greatest change in serum hemoglobin (MD=1.86, 95%CI= [1.20; 2.52]), ferritin (MD= -180.84, 95%CI= [-264.47; -97.20]), and total iron binding capacity (TIBC) (MD=11.03, 95%CI= [3.15; 18.92]) from baseline values. Dialysis-dependent patients with anemia had a significant increment in serum Hemoglobin and TIBC and a reduction in serum ferritin, in a dose-dependent manner, when administered daprodustat.
